Search results for "TYR"

showing 10 items of 2017 documents

Antikonvulsiva, 1. Mitt. Thiocarbamoylbutyroguanamine

1986

Durch Anlagerung von Butyroguanamin (1) an die Isothiocyanate 2a-c sind die Thiocarbamoylbutyroguanamine 3a-c zuganglich. Auf dem Wege der Acylierung von 3 sind unsymmetrisch substituierte Butyroguanamine 4 erhaltlich. Unter den neu entwickelten Verbindungen zeichnet sich insbesondere 3c durch antikonvulsive, fungizide und die Magensauresekretion hemmende Wirkungen aus. Anticonvulsivic Agents, I: Thiocarbamoylbutyroguanamines The thiocarbamoylbutyroguanamines 3a-c are accessible by addition of butyroguanamine (1) to the isothiocyanates 2a-c. Unsymmetrically substituted butyroguanamines 4 are obtainable by acylation of 3. Among the newly prepared compounds, 3c in particular exhibits anticonv…

Acylationchemistry.chemical_compoundChemistryStereochemistryDrug DiscoveryIsothiocyanateMass spectrumPharmaceutical ScienceButyroguanamineNuclear magnetic resonance spectroscopyInhibitory effectArchiv der Pharmazie
researchProduct

The Effect of Tyramine, Noradrenaline, and Angiotensin on the Blood Pressure in Hypertensive Patients with Aldosteronism and Low Plasma Renin

1970

The reactivity to the pressor action of tyramine, noradrenaline, and angiotensin was determined in 9 patients with hypertension, aldosteronism and low plasma renin concentration (4 patients with solitary adrenal adenomas, 3 patients with nodular adrenal hyperplasia, 2 patients with unknown adrenal status). In 7 patients tests were repeated following unilateral or subtotal adrenalectomy respectively. For comparison, 5 patients with phaeochromocytoma, 10 patients with benign essential hypertension, and 12 normotensive control subjects were studied. — In the hypertensive patients with aldosteronism and low plasma renin, responsiveness to tyramine was significantly reduced. In contrast, pressor…

AdenomaAdultMalemedicine.medical_specialtyClinical BiochemistryAdrenal Gland NeoplasmsTyramineAdrenergicBlood PressurePheochromocytomaBiochemistryPlasma renin activityPheochromocytomaNorepinephrinechemistry.chemical_compoundInternal medicineHyperaldosteronismReninRenin–angiotensin systemmedicineHumansbusiness.industryAngiotensin IIGeneral MedicineMiddle AgedTyraminemedicine.diseaseHyperaldosteronismAngiotensin IIBlood pressureEndocrinologychemistryHypertensionFemaleVascular ResistancebusinessEuropean Journal of Clinical Investigation
researchProduct

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1999

Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinomas. In this study, we screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET proto-oncogene. Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel missense mutations; three of five mutations were located in the ATP-binding region of t…

AdenomaModels MolecularCancer ResearchProtein ConformationDNA Mutational AnalysisMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaBiologymedicine.disease_causeTransfectionProto-Oncogene MasReceptor tyrosine kinaseMiceAdenosine TriphosphateNeoplastic Syndromes HereditaryProto-OncogenesGeneticsCarcinomamedicineMissense mutationAnimalsHumansPoint MutationAmino Acid SequencePhosphorylationCodonMolecular BiologyKidneyMutationBinding SitesSequence Homology Amino AcidPoint mutation3T3 CellsDNA NeoplasmProto-Oncogene Proteins c-metmedicine.diseaseCarcinoma PapillaryKidney NeoplasmsNeoplasm Proteinsmedicine.anatomical_structureCell Transformation NeoplasticCancer researchbiology.proteinMutagenesis Site-DirectedTyrosine kinaseProtein Processing Post-TranslationalSequence AlignmentOncogene
researchProduct

Epigenetic dysregulation in the developing Down syndrome cortex

2016

Using Illumina 450K arrays, 1.85% of all analyzed CpG sites were significantly hypermethylated and 0.31% hypomethylated in fetal Down syndrome (DS) cortex throughout the genome. The methylation changes on chromosome 21 appeared to be balanced between hypo- and hyper-methylation, whereas, consistent with prior reports, all other chromosomes showed 3–11 times more hyper- than hypo-methylated sites. Reduced NRSF/REST expression due to upregulation of DYRK1A (on chromosome 21q22.13) and methylation of REST binding sites during early developmental stages may contribute to this genome-wide excess of hypermethylated sites. Upregulation of DNMT3L (on chromosome 21q22.4) could lead to de novo methyl…

Adult0301 basic medicineCancer ResearchDown syndromeDown syndromeNeuronal OutgrowthDNMT3BProtein Serine-Threonine KinasesBiologyDNA Methyltransferase 3AEpigenesis Genetic03 medical and health sciencesfetal brain developmentddc:570medicineHumansDNA (Cytosine-5-)-MethyltransferasesEpigeneticsddc:610Molecular BiologyCerebral CortexGeneticsDNA methylationfrontal cortexGene Expression Regulation DevelopmentalChromosomeMethylationProtein-Tyrosine KinasesCadherinsmedicine.diseaseMolecular biologyprotocadherin gamma cluster030104 developmental biologyCpG siteDNA methylationChromosome 21Research Paper
researchProduct

Human liver cytosolic epoxide hydrolases.

1988

Human liver epoxide hydrolases were characterized by several criteria and a cytosolic cis-stilbene oxide hydrolase (cEHcso) was purified to apparent homogeneity. Styrene oxide and five phenylmethyloxiranes were tested as substrates for human liver epoxide hydrolases. With microsomes activity was highest with trans-2-methylstyrene oxide, followed by styrene 7, 8-oxide, cis-2-With methylstyrene oxide, cis-1,2-dimethylstyrene oxide, trans-1, 2-dimethylstyrene oxide and 2, 2-dimethylstyrene oxide. With cytosol the same order was obtained for the first three substrates, whereas activity with 2, 2-dimethylstyrene oxide was higher than with cis-1,2-dimethylstyrene oxide and no hydrolysis occurred …

AdultBiochemistryStyreneSubstrate Specificitychemistry.chemical_compoundCytosolStyrene oxideHydrolaseAnimalsHumansEpoxide hydrolaseEpoxide HydrolasesImmunochemistryChromatography Ion ExchangeRatsIsoelectric pointchemistryBiochemistryLiverMicrosomal epoxide hydrolaseEpoxide HydrolasesMicrosomeChromatography GelMicrosomes LiverEpoxy CompoundsElectrophoresis Polyacrylamide GelIsoelectric FocusingEuropean journal of biochemistry
researchProduct

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

Effect of gut-derived acetate on glucose turnover in man

1988

1. The effect of acetate absorbed from the gut on glucose turnover has been determined in four healthy subjects during both fasting and an intravenous glucose infusion by using [U-13C]glucose. 2. In the first part of the study, after an overnight fast, a tracer dose of [U-13C]glucose was infused at a constant rate along with an infusion of saline for 7 h. In the second part the saline infusion was replaced by glucose at 4.25 mg min−1 kg−1. In both studies 15 mmol of sodium acetate was given by mouth at 15 min intervals from the fourth to the sixth hour. Glucose turnover, respiratory quotient, metabolic rate and blood levels of acetate, 3-hydroxybutyrate, lactate, insulin, glucagon and gastr…

AdultDietary FiberGlycerolMalemedicine.medical_specialtymedicine.medical_treatmentHydroxybutyratesGastric Inhibitory PolypeptideAcetatesFatty Acids NonesterifiedCarbohydrate metabolismGlucagonAcetic acidchemistry.chemical_compoundGastric inhibitory polypeptideLipid oxidationInternal medicinemedicineHumansInsulinCarbon RadioisotopesAcetic Acid3-Hydroxybutyric AcidChemistryRespirationInsulinGeneral MedicineMetabolismCarbon DioxideGlucagonRespiratory quotientGlucoseEndocrinologyLactatesFemaleClinical Science
researchProduct

Effect of gut-derived acetate on oral glucose tolerance in man.

1988

1. Dietary fibre has a moderating impact on glucose metabolism. To test the hypothesis that this effect of fibre may be mediated by its breakdown product acetate, oral glucose tolerance tests were carried out in healthy volunteers with and without acetate. 2. Five subjects received 50 g of glucose orally while taking either acetate (15 mmol every 15 min) by mouth or chloride as control. Oral acetate made no detectable difference to glucose tolerance or to levels of free fatty acids, 3-hydroxybutyrate, lactate, insulin, glucagon and gastric inhibitory polypeptide. 3. The 50 g dose of glucose temporarily depressed acetate levels in blood. This was probably due to an interaction between glucos…

AdultDietary FiberMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentLumen (anatomy)HydroxybutyratesGastric Inhibitory PolypeptideXyloseCarbohydrate metabolismAcetatesFatty Acids NonesterifiedGlucagonchemistry.chemical_compoundGastric inhibitory polypeptideInternal medicinemedicine3-Hydroxybutyric AcidHumansInsulinGlucose tolerance testmedicine.diagnostic_test3-Hydroxybutyric AcidInsulinGeneral MedicineGlucose Tolerance TestGlucagonEndocrinologyGlucosechemistryLactatesFemaleClinical science (London, England : 1979)
researchProduct

Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy

2013

BACKGROUND & AIMS: Cirrhotic patients with minimal hepatic encephalopathy (MHE) show impaired driving ability and increased vehicle accidents. The neurological deficits contributing to impair driving and the underlying mechanisms are poorly understood. Early detection of driving impairment would help to reduce traffic accidents in MHE patients. It would be therefore useful to have psychometric or biochemical parameters reflecting driving impairment. The aims of this work were as follows: (i) to shed light on the neurological deficits contributing to impair driving; (ii) to assess whether some psychometric test or biochemical parameter is a good indicator of driving impairment. METHODS: We a…

AdultLiver Cirrhosismedicine.medical_specialtyAutomobile DrivingCirrhosisPsychometricsEncephalopathyPoison controlminimal hepatic encephalopathyAudiologyNitric Oxidepsychometric testsFlicker FusionmedicineHumansHepatic encephalopathyCyclic GMPAgedPsychomotor learning3-nitrotyrosineAnalysis of VarianceHepatologybusiness.industryDriving simulatorMiddle Agedmedicine.diseaseAnticipationfitness to driveMotor coordinationHepatic EncephalopathyPhysical therapyTyrosineChemokinesbusinesshuman activitiesBiomarkers
researchProduct